RBC 6-TGN and hematological parameters in patients with Crohn's disease treated by azathioprine

Gastroenterologie Clinique et Biologique

Volumn 29, Issue 12, 2005, Pages 1264-1269

  D'Halluin, Pierre Nicolas ^a   Tribut, Olivier ^a   Branger, Bernard ^a   Lebreton, Christine ^a   Bretagne, Jean François ^a   Bentue Ferrer, Danièle ^a   Heresbach, Denis ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; SALICYLIC ACID DERIVATIVE; TIOGUANINE;

ADULT; ARTICLE; BLOOD SAMPLING; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; ERYTHROCYTE; ERYTHROCYTE COUNT; FEMALE; HEMATOLOGICAL PARAMETERS; HEPARINIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOCYTE COUNT; LOGISTIC REGRESSION ANALYSIS; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MULTIVARIATE ANALYSIS; NEUTROPHIL COUNT; THROMBOCYTE COUNT;

EID: 31644436291     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(05)82219-5     Document Type: Article

References (45)

1. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2:944-7.
2. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105:367-72.
3. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
4. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med 1989;111:641-9.
5. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-42.
6. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-Mercaptopurine for inducing remission of Crohn's disease (Cochrane Review). Oxford: The Cochrane Library 2001 (3), update Software.
7. Lennard L, Maddocks JL. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells. J Pharm Pharmacol 1983;35:15-8.
8. Lennard L, Brown CB, Fox M, Maddocks JL. Azathioprine metabolism in kidney transplant recipients. Br J Clin Pharmacol 1984;18:693-700.
9. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
10. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-45.
11. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816-23.
12. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994;343:1188-90.
13. Bergan S, Rugstad HE, Bentdal O, Sodal G, Hartmann A, Leivestad T, et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplantation 1998;66:334-9.
14. Schutz E, Gummert J, Mohr FW, Armstrong VW, Oellerich M. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monit 1996;18:228-33.
15. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-6.
16. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
17. Roblin X, Serres Debeauvais F, Phelip JM, Pofelsky J, Bessard G, Bonaz B. Intérêt d'un monitorage précoce des 6-TGN au cours des MICI sous azathioprine : étude prospective chez 120 patients (abstract). Gastroenterol Clin Biol 2004;28:A9.
18. Belaiche J, Desager JP, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001;36:71-6.
19. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999;117:527-35.
20. Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49:665-70.
21. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996;39:401-6.
22. Sandborn WJ. 6-MP metabolite levels: a potential guide to Crohn's disease therapy. Gastroenterology 1997;113:690-2.
23. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
24. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992;583:83-90.
25. Wickramasinghe SN, Dodsworth H, Rault RM, Hulme B. Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplantation. Transplantation 1974;18:443-6.
26. Kirschner BS.Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813-21.
27. Jobson B, Garza A, Sninsky A. Red Cell Mean Corpuscular volume (VGM) correlates with 6 Thioguanine nucleotide (6TG) levels during azathioprine or 6-MP Therapy for Crohn's disease (abstract). Gastroenterology 2001;120 (Suppl 1):A18.
28. Garza A, Sninsky C. Change in red cell mean corpuscular volume (MCV) during azathioprine or 6-MP therapy for Crohn's disease may indicate optimal dose titration (abstract). Gastroenterology 2001;120(Suppll):A624.
29. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-9.
30. Thomas CW, Jr., Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, et al. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 2003;9:237-45.
31. Joy D, MacPherson R, Campbell S, Kingstone K, Ghosh S. Relationship of thiopurine methyltransferase (TPMT) activity to mean corpuscular volume (MCV) in inflammatory bowel disease (IBD) patients maintened on azathioprine (abstract). Gut 2002;50:A79.
32. Decaux G, Prospert F, Horsmans Y, Desager JP. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000;135:256-62.
33. Adhoot A, Toback J, Gotian A, Noyer C, Brandt L. Mean corpuscular volume (MCV) as a marker for 6-MMP and 6-TG, the toxic and active metabolites of 6-mercaptopurine (6-MP) (abstract). Am J Gastroenterol 2003;98:S240.
34. Cattan S, Lemann M, Thuillier F, Bengoufa D, Rabian C, Ngo Y, et al. Dosage de la 6-mercaptopurine et étude des sous populations lymphocytaires sanguines au cours du traitement par l'azathioprine dans la maladie de Crohn. Gastroenterol Clin Biol 1998;22:160-7.
35. Morowitz DA, Allen LW, Kirsner JB. Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med 1968;68:1013-21.
36. Talstad I, Rootwelt K, Gjone E. Thrombocytosis in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1973;8:135-8.
37. Harries AD, Fitzsimons E, Fifield R, Dew MJ, Rhoades J. Platelet count: a simple measure of activity in Crohn's disease. Br Med J (Clin Res Ed) 1983;286:1476.
38. Shah A, Morgan G, Rose JD, Fifield R, Rhodes J. Platelet number and size in relation to serum orosomucoid concentration in Crohn's disease. Med Lab Sci 1989;46:79-80.
39. Collins CE, Cahill MR, Rampton DS. Paradoxical association between increased platelet activation and reduced platelet volume in Crohn's disease (abstact). Gut 1993;34:S63.
40. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001;96:776-81.
41. Bernstein CN, Artinian L, Anton PA, Shanahan F. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Dig Dis Sci 1994;39:1638-41.
42. Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994;89:362-6.
43. Palance AL, Glazier KD. Absolute neutrophil count is a reliable predictor of clinical response in patients with moderate to severe inflammatory bowel disease treated with purinethol (6MP) (abstract). Gastroenterology 2002;122:S1395.
44. Campbell AC, Skinner JM, Maclennan IC, Hersey P, Waller CA, Wood J, et al. Immunosuppression in the treatment of inflammatory bowel disease. II. The effects of azathioprine on lymphoid cell populations in a double blind trial in ulcerative colitis. Clin Exp Immunol 1976;24:249-58.
45. Campbell S, Ghosh S. Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol 2001;13:1073-6.